CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Mutation

CIViC ID: 185 · Gene: BRCA1

Variant Summary

HGVS
Variant Type(s)
gene_variant,loss_of_function_variant
Evidence Items
21

Evidence Level Distribution

Level A: 5Level B: 16

Evidence Items

Showing CIViC evidence rows where gene = BRCA1 and variant = Mutation.

LevelTypeDirectionSignificanceDiseaseDrugsRating
APredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib5
APredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib5
APredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib5
APredictiveSupportsSensitivity/ResponseCastration-resistant Prostate CarcinomaOlaparib4
BPredictiveSupportsSensitivity/ResponseCancerOlaparib4
BPredictiveSupportsSensitivity/ResponseHer2-receptor Negative Breast CancerOlaparib4
BPredictiveSupportsSensitivity/ResponsePancreatic CancerOxaliplatin,Cisplatin4
BPredictiveSupportsSensitivity/ResponseOvarian CarcinomaPlatinum Compound3
BPredictiveSupportsSensitivity/ResponseOvarian CarcinomaPlatinum Compound3
BPrognosticSupportsBetter OutcomeOvarian Cancer3
BPredictiveSupportsSensitivity/ResponseOvarian CancerCediranib,Olaparib3
BPredictiveSupportsSensitivity/ResponseTriple-receptor Negative Breast CancerCisplatin,Carboplatin3
BPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib3
BPredictiveSupportsResistanceTriple-receptor Negative Breast CancerOlaparib3
BPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib3
BPrognosticSupportsBetter OutcomeEpithelial Ovarian Cancer3
BPredictiveSupportsSensitivity/ResponsePancreatic CancerOlaparib3
BPredictiveSupportsSensitivity/ResponsePancreatic CancerCisplatin,Gemcitabine,Veliparib3
BPredictiveDoes Not SupportSensitivity/ResponsePancreatic CancerVeliparib3
BPredictiveSupportsSensitivity/ResponseOvarian CancerRucaparib3
APredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib1